In the context of versatile liposomal constructs for co-delivery of tumor peptide epitopes in combination with TLR ligands, Thomann et al. performed a direct comparison between synthetic TLR2/1 and TLR2/6 agonists. Here, TLR2 is linked to neoplasm.